Submenu
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
ABOUT US
OUR SCIENCE
CLINICAL TRIALS
NEWS
CAREERS
FOR PATIENTS
PRESS RELEASES
NEWS COVERAGE
EVENTS
News

PRESS RELEASES

Featured press release
Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy
January 31, 2023

Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy

Glioblastoma
Melanoma
Bladder Cancer
Head and Neck Cancer
Istari
Filter by
2021
2020
Before 2020
Recent press releases
Istari Oncology Announces Presentation of Clinical Responses from LUMINOS-102, an ongoing Phase 2 Trial of Lerapolturev in anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 Congress
October 18, 2022

Istari Oncology Announces Presentation of Clinical Responses from LUMINOS-102, an ongoing Phase 2 Trial of Lerapolturev in anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 Congress

During 2022

Istari inc

Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)
November 9, 2021

Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)

During 2021

Head and Neck Cancer, Glioblastoma, Istari inc

Istari Oncology Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its Viral Immunotherapy PVSRIPO
October 26, 2021

Istari Oncology Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its Viral Immunotherapy PVSRIPO

During 2021

Istari inc

First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study
October 12, 2021

First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study

During 2021

Bladder Cancer

Istari Oncology Participates in Virtual Investor Conferences
September 7, 2021

Istari Oncology Participates in Virtual Investor Conferences

During 2021

Istari inc

Istari Oncology Initiates Its Phase 1/2 Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer
August 17, 2021

Istari Oncology Initiates Its Phase 1/2 Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer

During 2021

Head and Neck Cancer

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma
June 14, 2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

During 2021

Melanoma

Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team
June 7, 2021

Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team

During 2021

Istari inc

Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
June 1, 2021

Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

During 2021

Glioblastoma, Melanoma

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma
April 21, 2021

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma

During 2021

Melanoma